The role of the BCG dose and the mouse strain in the inhibition of development of neoplasms susceptible and nonsusceptible to the action of natural cytotoxic cells.
The susceptibility of Ehrlich Ascites Carcinoma (EAC) cells to the action of natural cytotoxic cells of DBA/2 and Balb/c mice in vitro was established. Leukaemia L 1210 cells proved insensitive to the in vitro action of natural cytotoxic cells of DBA/2 mice, but not to those of Balb/c ones. BCG, one of the inductors of cytotoxic NK cells, when administered to DBA/2 or Balb/c mice before introduction of EAC cells inhibited the growth of this tumour but did not retard the development of leukaemia L 1210 in DBA/2 mice. The change in the number of peritoneal exsudate cells (PEC) in DBA/2 mice after intraperitoneal injection of BCG was demonstrated to be dependent on the dose and the time elapsed after bacilli introduction. The antitumour action of BCG does not depend on changes in the number of PEC caused by the bacilli. Both large (3.0 mg) and small (0.02 mg) doses of BCG inhibit the development of EAC in Balb/c mice ("sensitive" to BCG), notwithstanding the time of administration of the bacilli. In DBA/2 mice ("resistant" to BCG) development of EAC can be inhibited only by the large dose of BCG since small one is sometimes ineffective.
D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage*; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology* / Q000628:therapy; D002470:Cell Survival; D003602:Cytotoxicity, Immunologic; D004198:Disease Susceptibility; D004306:Dose-Response Relationship, Immunologic; D007274:Injections, Intraperitoneal; D007694:Killer Cells, Natural / Q000276:immunology*; D007939:Leukemia L1210 / Q000276:immunology* / Q000628:therapy; D008264:Macrophages; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009504:Neutrophils; D013997:Time Factors
D001500:BCG Vaccine